Condition: Human Immunodeficiency Virus (HIV) · Cardiovascular Risk Factor · Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
This randomized, open-label clinical trial will evaluate whether adding fostemsavir to current antiretroviral therapy can reduce the risk of cardiovascular disease in people with well-controlled HIV. Researchers will compare imaging, clinical and biomarker outcomes between participants who receive fostemsavir in addition to their existing treatment and those who continue with standard care alone.
This description comes directly from the study's public registry record.
Branka Vulesevic, TRIAL MANAGER · 15148908000 · branka.vulesevic.chum@ssss.gouv.qc.ca
Madeleine Durand, STUDY SPONSOR · madeleine.durand@umontreal.ca
Always discuss trial participation with your own doctor first.
| CR CHUM | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07030920